|
|
|
Volumn 24, Issue 13, 2010, Pages 1-3
|
|
Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC ANTIMETABOLITE;
DIHYDROPYRIMIDINE DEHYDROGENASE;
DRUG DERIVATIVE;
FLUOROURACIL;
THYMIDYLATE SYNTHASE;
ARTICLE;
BIOMEDICAL TECHNOLOGY ASSESSMENT;
BLUE CROSS BLUE SHIELD;
COHORT ANALYSIS;
FOOD AND DRUG ADMINISTRATION;
GENETIC POLYMORPHISM;
GENETIC SCREENING;
GENETICS;
HUMAN;
METABOLISM;
NEOPLASM;
PHARMACOGENETICS;
PREDICTIVE VALUE;
UNITED STATES;
ANTIMETABOLITES, ANTINEOPLASTIC;
BLUE CROSS BLUE SHIELD INSURANCE PLANS;
COHORT STUDIES;
DIHYDROURACIL DEHYDROGENASE (NADP);
FLUOROURACIL;
GENETIC TESTING;
HUMANS;
NEOPLASMS;
PHARMACOGENETICS;
POLYMORPHISM, GENETIC;
PREDICTIVE VALUE OF TESTS;
TECHNOLOGY ASSESSMENT, BIOMEDICAL;
THYMIDYLATE SYNTHASE;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 79952051253
PISSN: None
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (3)
|
|
References (0)
|